EF Hutton Reiterates Buy on Xencor, Maintains $42 Price Target
EF Hutton analyst Michael King reiterates Xencor (NASDAQ:XNCR) with a Buy and maintains $42 price target.
Xencor Q4 EPS $(0.20) Beats $(0.79) Estimate, Sales $21.61M Beat $20.06M Estimate
Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.79) by 74.68 percent. This is a 116.53 percent decrease over earnings of $1.21 per share from the same
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
EF Hutton Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $42
EF Hutton analyst Michael King initiates coverage on Xencor (NASDAQ:XNCR) with a Buy rating and announces Price Target of $42.
EF Hutton Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $42
EF Hutton analyst Michael King initiates coverage on Xencor (NASDAQ:XNCR) with a Buy rating and announces Price Target of $42.
Xencor Presents Data From Phase 1 Study Of Plamotamab In Relapsed Or Refractory Non-Hodgkin Lymphoma At The American Society Of Hematology Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from
RBC Capital Maintains Outperform on Xencor, Lowers Price Target to $36
RBC Capital analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $40 to $36.
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell
• NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
JP Morgan Initiates Coverage On Xencor with Overweight Rating, Announces Price Target of $37
JP Morgan analyst Brian Cheng initiates coverage on Xencor (NASDAQ:XNCR) with a Overweight rating and announces Price Target of $37.